Insight

With advances in biomedical technology and evolving market demands, high-concentration protein preparations have emerged as a core focus in the biopharmaceutical industry owing to their compatibility with subcutaneous administration. Such dosage forms deliver remarkable clinical and commercial benefits. Clinically, subcutaneous injection enables self-administration, reduces hospital visits, improves medication compliance and cuts medical expenses. Commercially, it facilitates product upgrading, eases homogenization competition among drugs targeting identical targets and lowers risks associated with new drug research and development. Additionally, high-concentration protein preparations hold pivotal value for special administration routes such as intravitreal injection. Restricted by ocular anatomical characteristics, the injection volume is generally limited to ≤50µL with a maximum threshold of 100µL, a requirement perfectly satisfied by high-concentration protein formulations.

Market data of approved products indicates antibody drugs dominate the application of high-concentration protein preparations. Statistics on FDA-approved high-concentration antibody products from 1998 to 2023 reveal a steady growth trend. Notably, half of the 12 newly approved antibody drugs in 2023 were high-concentration formulations. Subcutaneous injection accounts for nearly 70% of administration routes among commercialized high-concentration antibody products.

Elevated protein concentration shortens intermolecular distance and triggers self-association networks, bringing about drastically increased solution viscosity and accelerated protein aggregation. Progressive concentration enrichment also raises the residual host cell protein (HCP) level, accompanied by higher esterase content. These enzymes substantially accelerate the degradation of polysorbate, a widely applied surfactant, impairing its protein stabilization efficacy.

Leveraging extensive practical experience in biopharmaceutical development and market-oriented R&D concepts, Ponovo Bio has established a dedicated development platform for high-concentration protein formulations. The platform balances R&D efficiency and success rate, providing robust technical support for rapid project progression.

High-concentration protein preparations confront multiple technical hurdles throughout development and manufacturing, including excessive viscosity, accelerated aggregation, rapid surfactant degradation, unstable protein concentration detection, pH drift and stringent HCP limits. Key challenges and corresponding solutions are elaborated as follows.

Solution viscosity exhibits strong positive correlation with protein concentration, predominantly governed by non-covalent intermolecular forces, especially electrostatic interaction. Such forces exert negligible impacts at low concentrations. As protein molecules draw closer under high concentration, intermolecular self-assembly forms network structures, leading to exponential viscosity growth. The acceptable viscosity threshold is capped at ≤20 cP for subcutaneous injection, while intravitreal injection demands stricter control below 10 cP.

Viscosity reduction relies on weakening intermolecular interactions via viscosity-lowering excipients. Common applicable additives include amino acids and inorganic salts such as L-arginine hydrochloride, sodium chloride and proline. The viscosity-reducing effect varies significantly with protein properties, excipient category and dosage, which requires customized screening for individual projects. Practical cases of Ponovo Bio prove optimal excipient combination can cut solution viscosity by up to 70%. The final target concentration is determined comprehensively based on clinical requirements, viscosity performance and product stability.

Protein aggregation originates from intermolecular attractive forces. Diversified aggregation mechanisms driven by complex protein structures generate aggregates in reversible or irreversible forms, ranging from soluble micro-particles to visible insoluble precipitates. High concentration narrows molecular spacing and raises collision frequency. Electrostatic force, van der Waals force and hydrophobic interaction collectively elevate aggregation risks.

Single-factor experiments and design of experiments (DOE) are adopted to screen optimal excipient combinations for stabilizing specific protein molecules. Distinct from conventional formulations, viscosity regulators may affect protein stability, hence refined concentration gradient investigation is essential. Ponovo Bio adopts an integrated evaluation system: nanoDSF and DSC characterize conformational stability, while kD analysis assesses colloidal stability to predict aggregation tendency. Combined with accelerated stability testing, this strategy shortens R&D cycles and mitigates formulation development risks effectively.

Polysorbate 20 and Polysorbate 80 serve as mainstream surfactants in protein formulations. Three degradation pathways including oxidation, hydrolysis and enzymatic degradation commonly occur under high-concentration conditions. Comparative studies are conducted in early R&D stage to identify dominant degradation causes, with trial additives such as methionine and EDTA, histidine-free buffer systems and enzyme inhibitors involved for targeted countermeasure formulation.

Enzymatic degradation is uniquely prominent in high-concentration systems. Esterase derived from residual HCP breaks ester bonds and deactivates polysorbate. HCP and endogenous esterase are concentrated synchronously with target protein during ultrafiltration, reaching the critical threshold triggering rapid surfactant decomposition. Effective mitigation strategies cover optimizing upstream and downstream processes to minimize esterase residues, switching to ester-free surfactants, and adopting lyophilized dosage forms to restrain enzymatic reaction.

High solid content results in compact lyophilized cake, poor wettability and low porosity, leading to lengthy reconstitution which may last several hours. Enhancing crystallization degree during freezing effectively shortens reconstitution duration by over 50% in industrial practices. Moderate concentration reduction is recommended if optimized reconstitution still fails to meet practical application demands.

Donnan effect induces specific ion adsorption on protein molecules, causing unexpected pH deviation. Preemptive pH calibration of buffer solution counteracts the drift tendency and maintains stable pH environment.

Over-concentration applied to improve recovery yield may trigger sharp viscosity surge and membrane fouling with minor concentration increment. Close cross-department communication ensures manufacturability under designated formulation parameters. Optimized membrane pore size, material selection and operational parameters reduce production risks in UFDF processes.

Traditional UV spectrophotometry requires high dilution for high-viscosity concentrated samples, introducing prominent operational errors and unstable test results. Direct undiluted detection technology matured in the industry greatly improves detection precision. Gravimetric dilution method is also applicable to minimize errors with density variation taken into consideration.

High-concentration protein preparations impose stringent technical requirements on upstream and downstream processing, formulation design, analytical testing and commercial manufacturing due to inherent drawbacks including high viscosity, aggregation propensity and surfactant instability. Efficient cross-departmental collaboration is indispensable for on-time project delivery. Ponovo Bio establishes dedicated project teams with flat management structure, eliminating communication barriers and realizing end-to-end seamless cooperation to maximize overall operational efficiency.